Amgen Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Amgen Inc. (AMGN) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-06-30 was $0.00.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-03-31 was -$363.00M.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $109.00M.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$21.00M, a 121.43% decline from fiscal 2023.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $98.00M.
- Amgen Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$165.00M, a 202.48% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | |||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-01 | ||||||
| 2025-12-31 | $109.00M 10-K · filed 2026-02-13 | ||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | -$335.00M 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2025-08-06 | -$384.00M derived: sum of 3 quarters · filed 2026-08-05 | -$384.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$363.00M 10-Q · filed 2026-05-01 | $0.00 10-Q · filed 2025-05-02 | -$384.00M derived: sum of 2 quarters · filed 2026-05-01 | -$384.00M derived: sum of 3 quarters · filed 2026-05-01 | -$384.00M derived: sum of 4 quarters · filed 2026-05-01 | ||
| 2024-12-31 | -$21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$21.00M derived: sum of 2 quarters · filed 2026-02-13 | -$21.00M derived: sum of 3 quarters · filed 2026-02-13 | -$21.00M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2025-08-06 | $0.00 10-Q · filed 2024-10-31 | $98.00M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | -$50.00M 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2025-08-06 | $98.00M derived: sum of 3 quarters · filed 2026-02-13 | $98.00M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-02 | $50.00M 10-Q · filed 2024-05-03 | $98.00M derived: sum of 2 quarters · filed 2026-02-13 | $98.00M derived: sum of 3 quarters · filed 2026-02-13 | $101.00M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2023-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $98.00M derived: sum of 2 quarters · filed 2026-02-13 | $101.00M derived: sum of 3 quarters · filed 2026-02-13 | $98.00M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | -$49.00M 10-Q · filed 2023-10-31 | $3.00M derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | -$41.00M 10-Q · filed 2023-10-31 | $102.00M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $8.00M 10-Q · filed 2023-08-04 | $102.00M derived: sum of 3 quarters · filed 2025-02-14 | $119.00M derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2023-03-31 | $5.00M 10-Q · filed 2024-05-03 | $99.00M derived: sum of 2 quarters · filed 2025-02-14 | $116.00M derived: sum of 3 quarters · filed 2025-02-14 | $10.00M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2022-12-31 | $94.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $111.00M derived: sum of 2 quarters · filed 2025-02-14 | $5.00M derived: sum of 3 quarters · filed 2025-02-14 | -$165.00M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | $17.00M 10-Q · filed 2023-10-31 | -$89.00M derived: sum of 2 quarters · filed 2023-10-31 | -$259.00M 10-Q · filed 2023-10-31 | -$202.00M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-06-30 | -$106.00M 10-Q · filed 2023-08-04 | -$276.00M 10-Q · filed 2023-08-04 | -$219.00M derived: sum of 3 quarters · filed 2024-02-14 | -$84.00M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-03-31 | -$170.00M 10-Q · filed 2023-04-28 | -$113.00M derived: sum of 2 quarters · filed 2024-02-14 | $22.00M derived: sum of 3 quarters · filed 2024-02-14 | $47.00M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2021-12-31 | $57.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $192.00M derived: sum of 2 quarters · filed 2024-02-14 | $217.00M derived: sum of 3 quarters · filed 2024-02-14 | $161.00M 10-K · filed 2024-02-14 | |||
| 2021-09-30 | $135.00M 10-Q · filed 2022-11-04 | $160.00M derived: sum of 2 quarters · filed 2022-11-04 | $104.00M 10-Q · filed 2022-11-04 | $213.00M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-06-30 | $25.00M 10-Q · filed 2022-08-05 | -$31.00M 10-Q · filed 2022-08-05 | $78.00M derived: sum of 3 quarters · filed 2023-02-09 | $138.00M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-03-31 | -$56.00M 10-Q · filed 2022-04-28 | $53.00M derived: sum of 2 quarters · filed 2023-02-09 | $113.00M derived: sum of 3 quarters · filed 2023-02-09 | $193.00M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2020-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $169.00M derived: sum of 2 quarters · filed 2023-02-09 | $249.00M derived: sum of 3 quarters · filed 2023-02-09 | $174.00M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | $60.00M 10-Q · filed 2021-11-03 | $140.00M derived: sum of 2 quarters · filed 2021-11-03 | $65.00M 10-Q · filed 2021-11-03 | $134.00M derived: sum of 4 quarters · filed 2022-02-16 | |||
| 2020-06-30 | $80.00M 10-Q · filed 2021-08-04 | $5.00M 10-Q · filed 2021-08-04 | $74.00M derived: sum of 3 quarters · filed 2022-02-16 | $59.00M derived: sum of 4 quarters · filed 2022-02-16 | |||
| 2020-03-31 | -$76.00M 10-Q · filed 2021-04-28 | -$6.00M derived: sum of 2 quarters · filed 2022-02-16 | -$21.00M derived: sum of 3 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $55.00M derived: sum of 2 quarters · filed 2022-02-16 | $112.00M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | -$15.00M 10-Q · filed 2020-10-29 | $42.00M 10-Q · filed 2020-10-29 | |||||
| 2018-12-31 | -$24.00M 10-K · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |